<DOC>
	<DOC>NCT00169624</DOC>
	<brief_summary>Peripheral and coronary endothelial dysfunction in type 2 diabetic patients may be influenced by therapeutics. Using Radial flow monitoring and myocardial perfusion magnetic resonance imaging, we designed a controlled randomized double blind study to test the hypothesis that endothelial dysfunction will be reversed following 3 months of Metformin administration vs gliclazide. 30 patients will be included.</brief_summary>
	<brief_title>Peripheral and Coronary Endothelial Dysfunction In Type 2diabetic Patients- Role of Metformin</brief_title>
	<detailed_description />
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Gliclazide</mesh_term>
	<criteria>1870 years old, type 2 diabetes, non significant coronary atherosclerosis on inclusion coronary angiogram (ie no coronary stenosis &gt; 70%), HbA1c&lt;9% significant coronary stenosis (&gt;70%), lack of informed consent, unstable hypertension, renal failure, contraindication to metformin or gliclazide, pregnancy, atrial fibrillation, contraindication to MRI, or to adenosine, brachial artery calcifications</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Diabetes,</keyword>
	<keyword>coronary endothelial dysfunction,</keyword>
	<keyword>metformin,</keyword>
	<keyword>glyclazide,</keyword>
	<keyword>MRI.</keyword>
</DOC>